Document is current
Any future updates will be listed below
-
Authors
Lewis, Tamorah https://orcid.org/0000-0003-2137-8339
Jensen, Erik A.
Courtney, Sherry https://orcid.org/0000-0003-1180-6598
Slaughter, Jonathan https://orcid.org/0000-0001-6831-7520
Kielt, Matthew J. https://orcid.org/0000-0002-4568-9070
Iyer, Narayan Prahbu https://orcid.org/0000-0003-3589-0018
Gauldin, Cheri
Nitkin, Christopher https://orcid.org/0000-0001-5718-4523
Yeh, Hung-Wen https://orcid.org/0000-0002-9904-3275
Truog, William
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (1R21HD101111, 1R21HD101111)
The Sellers Chair in Pharmacology and Pharmacogenetics, SickKids Foundation
- License Information
-
More Information
Article History
Received: 19 August 2024
Revised: 4 November 2024
Accepted: 8 November 2024
First Online: 21 November 2024
Competing interests
: The authors declare no competing interests.
: Children’s Mercy Hospital IRB approved the study at the primary site in Kansas City, Missouri (REB #1000080681). Each site had local IRB approval prior to patient enrollment and data collection. All methods were performed in accordance with the relevant regulations and IRB approved protocol. Informed consent was obtained from all parents of infants in the study.
